Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) Stock Competitors & Peer Comparison
See DNA-WT's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for DNA-WT and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DNA-WT | $0.27 | -2.76% | 18.7B | N/A | N/A | N/A |
| VRTX | $547.09 | +0.85% | 138.6B | 28.74 | $19.03 | N/A |
| MRNA | $254.19 | +5.27% | 101.5B | -31.20 | -$8.15 | N/A |
| REGN | $904.35 | +0.16% | 93.6B | 19.82 | $45.63 | +0.41% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $927.21 | +3.63% | 55.3B | 33.44 | $27.73 | N/A |
| ONC | $406.96 | +5.09% | 43.5B | 71.66 | $5.68 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMDW | $9.90 | +16.47% | 41.4B | -1.12 | -$8.82 | N/A |
| RVMD | $192.28 | +8.24% | 41.2B | -21.79 | -$8.82 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
DNA-WT vs VRTX Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, VRTX has a market cap of 138.6B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while VRTX trades at $547.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas VRTX's P/E ratio is 28.74. In terms of profitability, DNA-WT's ROE is -0.57%, compared to VRTX's ROE of +0.20%. Regarding short-term risk, DNA-WT is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check VRTX's competition here
Moderna, Inc. (NASDAQ: MRNA)
DNA-WT vs MRNA Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, MRNA has a market cap of 101.5B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while MRNA trades at $254.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas MRNA's P/E ratio is -31.20. In terms of profitability, DNA-WT's ROE is -0.57%, compared to MRNA's ROE of -0.38%. Regarding short-term risk, DNA-WT is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check MRNA's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
DNA-WT vs REGN Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, REGN has a market cap of 93.6B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while REGN trades at $904.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas REGN's P/E ratio is 19.82. In terms of profitability, DNA-WT's ROE is -0.57%, compared to REGN's ROE of +0.15%. Regarding short-term risk, DNA-WT is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
DNA-WT vs VRNA Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas VRNA's P/E ratio is -102.80. In terms of profitability, DNA-WT's ROE is -0.57%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, DNA-WT is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
DNA-WT vs ARGX Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ARGX has a market cap of 55.3B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while ARGX trades at $927.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ARGX's P/E ratio is 33.44. In terms of profitability, DNA-WT's ROE is -0.57%, compared to ARGX's ROE of +0.17%. Regarding short-term risk, DNA-WT is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check ARGX's competition here
BeOne Medicines AG (NASDAQ: ONC)
DNA-WT vs ONC Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ONC has a market cap of 43.5B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while ONC trades at $406.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ONC's P/E ratio is 71.66. In terms of profitability, DNA-WT's ROE is -0.57%, compared to ONC's ROE of +0.18%. Regarding short-term risk, DNA-WT is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check ONC's competition here
Seagen Inc. (NASDAQ: SGEN)
DNA-WT vs SGEN Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas SGEN's P/E ratio is -57.19. In terms of profitability, DNA-WT's ROE is -0.57%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, DNA-WT is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check SGEN's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
DNA-WT vs RVMDW Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, RVMDW has a market cap of 41.4B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while RVMDW trades at $9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas RVMDW's P/E ratio is -1.12. In terms of profitability, DNA-WT's ROE is -0.57%, compared to RVMDW's ROE of -0.92%. Regarding short-term risk, DNA-WT is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
DNA-WT vs RVMD Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, RVMD has a market cap of 41.2B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while RVMD trades at $192.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas RVMD's P/E ratio is -21.79. In terms of profitability, DNA-WT's ROE is -0.57%, compared to RVMD's ROE of -0.92%. Regarding short-term risk, DNA-WT is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check RVMD's competition here
Genmab A/S (NASDAQ: GMAB)
DNA-WT vs GMAB Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, GMAB has a market cap of 33B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while GMAB trades at $53.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas GMAB's P/E ratio is 40.41. In terms of profitability, DNA-WT's ROE is -0.57%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, DNA-WT is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check GMAB's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
DNA-WT vs ROIV Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ROIV has a market cap of 28.1B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while ROIV trades at $38.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ROIV's P/E ratio is -37.00. In terms of profitability, DNA-WT's ROE is -0.57%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, DNA-WT is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
DNA-WT vs INSM Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, INSM has a market cap of 25.1B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while INSM trades at $114.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas INSM's P/E ratio is -40.59. In terms of profitability, DNA-WT's ROE is -0.57%, compared to INSM's ROE of -0.83%. Regarding short-term risk, DNA-WT is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check INSM's competition here
Incyte Corporation (NASDAQ: INCY)
DNA-WT vs INCY Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, INCY has a market cap of 24.4B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while INCY trades at $119.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas INCY's P/E ratio is 16.08. In terms of profitability, DNA-WT's ROE is -0.57%, compared to INCY's ROE of +0.07%. Regarding short-term risk, DNA-WT is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check INCY's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
DNA-WT vs UTHR Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, UTHR has a market cap of 24.1B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while UTHR trades at $562.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas UTHR's P/E ratio is 20.11. In terms of profitability, DNA-WT's ROE is -0.57%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, DNA-WT is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check UTHR's competition here
BioNTech SE (NASDAQ: BNTX)
DNA-WT vs BNTX Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, BNTX has a market cap of 21.7B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while BNTX trades at $87.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas BNTX's P/E ratio is -11.35. In terms of profitability, DNA-WT's ROE is -0.57%, compared to BNTX's ROE of -0.08%. Regarding short-term risk, DNA-WT is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check BNTX's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
DNA-WT vs ALNY Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ALNY has a market cap of 20.9B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while ALNY trades at $155.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ALNY's P/E ratio is 7.87. In terms of profitability, DNA-WT's ROE is -0.57%, compared to ALNY's ROE of +1.60%. Regarding short-term risk, DNA-WT is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check ALNY's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
DNA-WT vs BGNE Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas BGNE's P/E ratio is -22.55. In terms of profitability, DNA-WT's ROE is -0.57%, compared to BGNE's ROE of +0.18%. Regarding short-term risk, DNA-WT is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check BGNE's competition here
Exelixis, Inc. (NASDAQ: EXEL)
DNA-WT vs EXEL Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, EXEL has a market cap of 17.5B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while EXEL trades at $69.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas EXEL's P/E ratio is 19.87. In terms of profitability, DNA-WT's ROE is -0.57%, compared to EXEL's ROE of +0.46%. Regarding short-term risk, DNA-WT is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check EXEL's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
DNA-WT vs ASND Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ASND has a market cap of 16.9B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while ASND trades at $256.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ASND's P/E ratio is -106.12. In terms of profitability, DNA-WT's ROE is -0.57%, compared to ASND's ROE of +1.90%. Regarding short-term risk, DNA-WT is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
DNA-WT vs NBIX Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, NBIX has a market cap of 16.7B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while NBIX trades at $164.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas NBIX's P/E ratio is 23.79. In terms of profitability, DNA-WT's ROE is -0.57%, compared to NBIX's ROE of +0.20%. Regarding short-term risk, DNA-WT is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
DNA-WT vs JAZZ Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, JAZZ has a market cap of 15.1B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while JAZZ trades at $234.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas JAZZ's P/E ratio is 8.75. In terms of profitability, DNA-WT's ROE is -0.57%, compared to JAZZ's ROE of +0.05%. Regarding short-term risk, DNA-WT is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
DNA-WT vs BBIO Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, BBIO has a market cap of 14.5B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while BBIO trades at $74.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas BBIO's P/E ratio is -24.43. In terms of profitability, DNA-WT's ROE is -0.57%, compared to BBIO's ROE of +0.27%. Regarding short-term risk, DNA-WT is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check BBIO's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
DNA-WT vs SMMT Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, SMMT has a market cap of 13B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while SMMT trades at $16.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas SMMT's P/E ratio is -14.58. In terms of profitability, DNA-WT's ROE is -0.57%, compared to SMMT's ROE of -1.59%. Regarding short-term risk, DNA-WT is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check SMMT's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
DNA-WT vs KRTX Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas KRTX's P/E ratio is -28.09. In terms of profitability, DNA-WT's ROE is -0.57%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, DNA-WT is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check KRTX's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
DNA-WT vs HALO Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, HALO has a market cap of 11.8B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while HALO trades at $103.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas HALO's P/E ratio is 19.35. In terms of profitability, DNA-WT's ROE is -0.57%, compared to HALO's ROE of +5.44%. Regarding short-term risk, DNA-WT is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check HALO's competition here
Bio-Techne Corporation (NASDAQ: TECH)
DNA-WT vs TECH Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while TECH trades at $72.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas TECH's P/E ratio is 37.52. In terms of profitability, DNA-WT's ROE is -0.57%, compared to TECH's ROE of +0.09%. Regarding short-term risk, DNA-WT is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
DNA-WT vs RNAM Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas RNAM's P/E ratio is -17.39. In terms of profitability, DNA-WT's ROE is -0.57%, compared to RNAM's ROE of -0.36%. Regarding short-term risk, DNA-WT is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check RNAM's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
DNA-WT vs KYMR Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, KYMR has a market cap of 11.2B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while KYMR trades at $131.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas KYMR's P/E ratio is -36.38. In terms of profitability, DNA-WT's ROE is -0.57%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, DNA-WT is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check KYMR's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
DNA-WT vs BMRN Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, BMRN has a market cap of 10.8B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while BMRN trades at $56.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas BMRN's P/E ratio is 26.93. In terms of profitability, DNA-WT's ROE is -0.57%, compared to BMRN's ROE of -0.00%. Regarding short-term risk, DNA-WT is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check BMRN's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
DNA-WT vs PCVX Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, PCVX has a market cap of 10B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while PCVX trades at $63.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas PCVX's P/E ratio is -8.37. In terms of profitability, DNA-WT's ROE is -0.57%, compared to PCVX's ROE of -0.42%. Regarding short-term risk, DNA-WT is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check PCVX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
DNA-WT vs SYRE Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, SYRE has a market cap of 9.6B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while SYRE trades at $103.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas SYRE's P/E ratio is -53.26. In terms of profitability, DNA-WT's ROE is -0.57%, compared to SYRE's ROE of -0.30%. Regarding short-term risk, DNA-WT is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check SYRE's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
DNA-WT vs RXDX Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas RXDX's P/E ratio is -56.47. In terms of profitability, DNA-WT's ROE is -0.57%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, DNA-WT is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check RXDX's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
DNA-WT vs MDGL Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, MDGL has a market cap of 9.2B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while MDGL trades at $399.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas MDGL's P/E ratio is -31.27. In terms of profitability, DNA-WT's ROE is -0.57%, compared to MDGL's ROE of -0.27%. Regarding short-term risk, DNA-WT is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check MDGL's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
DNA-WT vs TGTX Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, TGTX has a market cap of 9.2B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while TGTX trades at $59.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas TGTX's P/E ratio is 21.68. In terms of profitability, DNA-WT's ROE is -0.57%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, DNA-WT is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check TGTX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
DNA-WT vs IBRX Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, IBRX has a market cap of 9.1B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while IBRX trades at $8.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas IBRX's P/E ratio is -8.90. In terms of profitability, DNA-WT's ROE is -0.57%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, DNA-WT is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check IBRX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
DNA-WT vs NUVL Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas NUVL's P/E ratio is -21.79. In terms of profitability, DNA-WT's ROE is -0.57%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, DNA-WT is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
DNA-WT vs CRNX Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas CRNX's P/E ratio is -16.86. In terms of profitability, DNA-WT's ROE is -0.57%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, DNA-WT is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check CRNX's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
DNA-WT vs KRYS Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, KRYS has a market cap of 8.9B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while KRYS trades at $300.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas KRYS's P/E ratio is 37.68. In terms of profitability, DNA-WT's ROE is -0.57%, compared to KRYS's ROE of +0.17%. Regarding short-term risk, DNA-WT is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check KRYS's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
DNA-WT vs IMGN Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas IMGN's P/E ratio is -111.55. In terms of profitability, DNA-WT's ROE is -0.57%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, DNA-WT is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check IMGN's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
DNA-WT vs PTGX Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, PTGX has a market cap of 8.5B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while PTGX trades at $132.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas PTGX's P/E ratio is 128.05. In terms of profitability, DNA-WT's ROE is -0.57%, compared to PTGX's ROE of +0.43%. Regarding short-term risk, DNA-WT is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check PTGX's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
DNA-WT vs APGE Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas APGE's P/E ratio is -31.19. In terms of profitability, DNA-WT's ROE is -0.57%, compared to APGE's ROE of -0.30%. Regarding short-term risk, DNA-WT is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check APGE's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
DNA-WT vs BPMC Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas BPMC's P/E ratio is -51.58. In terms of profitability, DNA-WT's ROE is -0.57%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, DNA-WT is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check BPMC's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
DNA-WT vs ARWR Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ARWR has a market cap of 8.2B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while ARWR trades at $58.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ARWR's P/E ratio is -25.84. In terms of profitability, DNA-WT's ROE is -0.57%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, DNA-WT is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check ARWR's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
DNA-WT vs CERE Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas CERE's P/E ratio is -16.47. In terms of profitability, DNA-WT's ROE is -0.57%, compared to CERE's ROE of -0.72%. Regarding short-term risk, DNA-WT is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check CERE's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
DNA-WT vs TWST Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, TWST has a market cap of 8B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while TWST trades at $120.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas TWST's P/E ratio is -54.47. In terms of profitability, DNA-WT's ROE is -0.57%, compared to TWST's ROE of -0.30%. Regarding short-term risk, DNA-WT is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check TWST's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
DNA-WT vs PRAX Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, PRAX has a market cap of 7.8B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while PRAX trades at $277.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas PRAX's P/E ratio is -21.49. In terms of profitability, DNA-WT's ROE is -0.57%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, DNA-WT is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check PRAX's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
DNA-WT vs RYTM Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, RYTM has a market cap of 7.7B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while RYTM trades at $112.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas RYTM's P/E ratio is -36.07. In terms of profitability, DNA-WT's ROE is -0.57%, compared to RYTM's ROE of -0.84%. Regarding short-term risk, DNA-WT is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check RYTM's competition here
Abivax S.A. (NASDAQ: ABVX)
DNA-WT vs ABVX Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ABVX has a market cap of 7.5B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while ABVX trades at $85.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ABVX's P/E ratio is -14.06. In terms of profitability, DNA-WT's ROE is -0.57%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, DNA-WT is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check ABVX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
DNA-WT vs CYTK Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CYTK has a market cap of 7.5B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while CYTK trades at $53.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas CYTK's P/E ratio is -7.44. In terms of profitability, DNA-WT's ROE is -0.57%, compared to CYTK's ROE of +1.57%. Regarding short-term risk, DNA-WT is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check CYTK's competition here
Metsera, Inc. (NASDAQ: MTSR)
DNA-WT vs MTSR Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas MTSR's P/E ratio is -23.58. In terms of profitability, DNA-WT's ROE is -0.57%, compared to MTSR's ROE of -0.47%. Regarding short-term risk, DNA-WT is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check MTSR's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
DNA-WT vs CAI Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CAI has a market cap of 7.1B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while CAI trades at $25.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas CAI's P/E ratio is 70.92. In terms of profitability, DNA-WT's ROE is -0.57%, compared to CAI's ROE of +0.16%. Regarding short-term risk, DNA-WT is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check CAI's competition here
10x Genomics, Inc. (NASDAQ: TXG)
DNA-WT vs TXG Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, TXG has a market cap of 7.1B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while TXG trades at $59.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas TXG's P/E ratio is -100.53. In terms of profitability, DNA-WT's ROE is -0.57%, compared to TXG's ROE of -0.08%. Regarding short-term risk, DNA-WT is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check TXG's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
DNA-WT vs AXSM Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, AXSM has a market cap of 7B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while AXSM trades at $132.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas AXSM's P/E ratio is -34.56. In terms of profitability, DNA-WT's ROE is -0.57%, compared to AXSM's ROE of -1.90%. Regarding short-term risk, DNA-WT is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check AXSM's competition here
Merus N.V. (NASDAQ: MRUS)
DNA-WT vs MRUS Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas MRUS's P/E ratio is -17.05. In terms of profitability, DNA-WT's ROE is -0.57%, compared to MRUS's ROE of -0.31%. Regarding short-term risk, DNA-WT is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check MRUS's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
DNA-WT vs ORKA Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ORKA has a market cap of 6.8B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while ORKA trades at $102.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ORKA's P/E ratio is -52.98. In terms of profitability, DNA-WT's ROE is -0.57%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, DNA-WT is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check ORKA's competition here
CG Oncology Inc. (NASDAQ: CGON)
DNA-WT vs CGON Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CGON has a market cap of 6.7B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while CGON trades at $75.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas CGON's P/E ratio is -28.25. In terms of profitability, DNA-WT's ROE is -0.57%, compared to CGON's ROE of -0.19%. Regarding short-term risk, DNA-WT is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check CGON's competition here
Arcellx, Inc. (NASDAQ: ACLX)
DNA-WT vs ACLX Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ACLX's P/E ratio is -28.27. In terms of profitability, DNA-WT's ROE is -0.57%, compared to ACLX's ROE of -0.40%. Regarding short-term risk, DNA-WT is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
DNA-WT vs RETA Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas RETA's P/E ratio is -66.29. In terms of profitability, DNA-WT's ROE is -0.57%, compared to RETA's ROE of +0.47%. Regarding short-term risk, DNA-WT is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check RETA's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
DNA-WT vs IONS Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, IONS has a market cap of 6.5B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while IONS trades at $39.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas IONS's P/E ratio is -12.05. In terms of profitability, DNA-WT's ROE is -0.57%, compared to IONS's ROE of -1.11%. Regarding short-term risk, DNA-WT is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check IONS's competition here
Immunovant, Inc. (NASDAQ: IMVT)
DNA-WT vs IMVT Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, IMVT has a market cap of 6.3B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while IMVT trades at $30.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas IMVT's P/E ratio is -10.82. In terms of profitability, DNA-WT's ROE is -0.57%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, DNA-WT is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check IMVT's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
DNA-WT vs CNTA Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas CNTA's P/E ratio is -22.63. In terms of profitability, DNA-WT's ROE is -0.57%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, DNA-WT is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check CNTA's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
DNA-WT vs KOD Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, KOD has a market cap of 6.2B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while KOD trades at $99.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas KOD's P/E ratio is -23.82. In terms of profitability, DNA-WT's ROE is -0.57%, compared to KOD's ROE of -2.73%. Regarding short-term risk, DNA-WT is less volatile compared to KOD. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check KOD's competition here
Belite Bio, Inc (NASDAQ: BLTE)
DNA-WT vs BLTE Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, BLTE has a market cap of 6.1B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while BLTE trades at $154.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas BLTE's P/E ratio is -82.52. In terms of profitability, DNA-WT's ROE is -0.57%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, DNA-WT is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check BLTE's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
DNA-WT vs LGND Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, LGND has a market cap of 6.1B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while LGND trades at $306.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas LGND's P/E ratio is 33.58. In terms of profitability, DNA-WT's ROE is -0.57%, compared to LGND's ROE of +0.05%. Regarding short-term risk, DNA-WT is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check LGND's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
DNA-WT vs TERN Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, TERN has a market cap of 6.1B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas TERN's P/E ratio is -51.41. In terms of profitability, DNA-WT's ROE is -0.57%, compared to TERN's ROE of -0.14%. Regarding short-term risk, DNA-WT is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check TERN's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
DNA-WT vs MIRM Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, MIRM has a market cap of 6.1B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while MIRM trades at $93.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas MIRM's P/E ratio is -6.44. In terms of profitability, DNA-WT's ROE is -0.57%, compared to MIRM's ROE of -7.34%. Regarding short-term risk, DNA-WT is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check MIRM's competition here
Veradermics, Incorporated (NYSE: MANE)
DNA-WT vs MANE Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, MANE has a market cap of 5.8B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while MANE trades at $138.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas MANE's P/E ratio is -44.17. In terms of profitability, DNA-WT's ROE is -0.57%, compared to MANE's ROE of -0.38%. Regarding short-term risk, DNA-WT is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check MANE's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
DNA-WT vs SRRK Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while SRRK trades at $46.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas SRRK's P/E ratio is -13.60. In terms of profitability, DNA-WT's ROE is -0.57%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, DNA-WT is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check SRRK's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
DNA-WT vs CDTX Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas CDTX's P/E ratio is -19.77. In terms of profitability, DNA-WT's ROE is -0.57%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, DNA-WT is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
DNA-WT vs ABCM Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, DNA-WT's ROE is -0.57%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, DNA-WT is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
DNA-WT vs ISEE Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ISEE's P/E ratio is -22.44. In terms of profitability, DNA-WT's ROE is -0.57%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, DNA-WT is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check ISEE's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
DNA-WT vs COGT Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, COGT has a market cap of 5.5B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while COGT trades at $31.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas COGT's P/E ratio is -15.00. In terms of profitability, DNA-WT's ROE is -0.57%, compared to COGT's ROE of -0.71%. Regarding short-term risk, DNA-WT is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check COGT's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
DNA-WT vs PTCT Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, PTCT has a market cap of 5.5B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while PTCT trades at $65.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas PTCT's P/E ratio is -46.74. In terms of profitability, DNA-WT's ROE is -0.57%, compared to PTCT's ROE of +0.57%. Regarding short-term risk, DNA-WT is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check PTCT's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
DNA-WT vs APLS Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas APLS's P/E ratio is 38.35. In terms of profitability, DNA-WT's ROE is -0.57%, compared to APLS's ROE of +0.40%. Regarding short-term risk, DNA-WT is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check APLS's competition here
Erasca, Inc. (NASDAQ: ERAS)
DNA-WT vs ERAS Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ERAS has a market cap of 5B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while ERAS trades at $14.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ERAS's P/E ratio is -15.49. In terms of profitability, DNA-WT's ROE is -0.57%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, DNA-WT is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check ERAS's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
DNA-WT vs CRSP Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CRSP has a market cap of 4.9B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while CRSP trades at $50.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas CRSP's P/E ratio is -10.52. In terms of profitability, DNA-WT's ROE is -0.57%, compared to CRSP's ROE of -0.26%. Regarding short-term risk, DNA-WT is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check CRSP's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
DNA-WT vs EWTX Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, EWTX has a market cap of 4.9B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while EWTX trades at $45.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas EWTX's P/E ratio is -24.37. In terms of profitability, DNA-WT's ROE is -0.57%, compared to EWTX's ROE of +1.30%. Regarding short-term risk, DNA-WT is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check EWTX's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
DNA-WT vs DNTH Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, DNTH has a market cap of 4.8B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while DNTH trades at $86.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas DNTH's P/E ratio is -20.72. In terms of profitability, DNA-WT's ROE is -0.57%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, DNA-WT is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check DNTH's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
DNA-WT vs TVTX Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, TVTX has a market cap of 4.8B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while TVTX trades at $49.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas TVTX's P/E ratio is -110.27. In terms of profitability, DNA-WT's ROE is -0.57%, compared to TVTX's ROE of -1.86%. Regarding short-term risk, DNA-WT is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check TVTX's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
DNA-WT vs FOLD Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas FOLD's P/E ratio is -161.00. In terms of profitability, DNA-WT's ROE is -0.57%, compared to FOLD's ROE of -0.02%. Regarding short-term risk, DNA-WT is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
DNA-WT vs AKRO Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas AKRO's P/E ratio is -14.57. In terms of profitability, DNA-WT's ROE is -0.57%, compared to AKRO's ROE of -0.15%. Regarding short-term risk, DNA-WT is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check AKRO's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
DNA-WT vs DFTX Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, DFTX has a market cap of 4.5B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while DFTX trades at $33.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas DFTX's P/E ratio is N/A. In terms of profitability, DNA-WT's ROE is -0.57%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, DNA-WT is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check DFTX's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
DNA-WT vs ADPT Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ADPT has a market cap of 4.5B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while ADPT trades at $27.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ADPT's P/E ratio is -68.20. In terms of profitability, DNA-WT's ROE is -0.57%, compared to ADPT's ROE of -0.37%. Regarding short-term risk, DNA-WT is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check ADPT's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
DNA-WT vs ALPN Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ALPN's P/E ratio is -101.52. In terms of profitability, DNA-WT's ROE is -0.57%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, DNA-WT is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check ALPN's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
DNA-WT vs LEGN Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, LEGN has a market cap of 4.3B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while LEGN trades at $23.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas LEGN's P/E ratio is -34.41. In terms of profitability, DNA-WT's ROE is -0.57%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, DNA-WT is more volatile compared to LEGN. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check LEGN's competition here
Opthea Limited (NASDAQ: OPT)
DNA-WT vs OPT Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas OPT's P/E ratio is -1.52. In terms of profitability, DNA-WT's ROE is -0.57%, compared to OPT's ROE of +1.18%. Regarding short-term risk, DNA-WT is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
DNA-WT vs PRTC Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas PRTC's P/E ratio is -3.78. In terms of profitability, DNA-WT's ROE is -0.57%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, DNA-WT is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check PRTC's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
DNA-WT vs MRTX Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas MRTX's P/E ratio is -4.82. In terms of profitability, DNA-WT's ROE is -0.57%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, DNA-WT is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check MRTX's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
DNA-WT vs RLAY Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, RLAY has a market cap of 4.1B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while RLAY trades at $18.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas RLAY's P/E ratio is -11.85. In terms of profitability, DNA-WT's ROE is -0.57%, compared to RLAY's ROE of -0.40%. Regarding short-term risk, DNA-WT is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check RLAY's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
DNA-WT vs CPRX Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas CPRX's P/E ratio is 17.49. In terms of profitability, DNA-WT's ROE is -0.57%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, DNA-WT is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check CPRX's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
DNA-WT vs ABCL Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ABCL has a market cap of 3.9B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while ABCL trades at $11.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ABCL's P/E ratio is -22.01. In terms of profitability, DNA-WT's ROE is -0.57%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, DNA-WT is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check ABCL's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
DNA-WT vs XENE Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, XENE has a market cap of 3.8B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while XENE trades at $39.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas XENE's P/E ratio is -8.34. In terms of profitability, DNA-WT's ROE is -0.57%, compared to XENE's ROE of -0.44%. Regarding short-term risk, DNA-WT is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check XENE's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
DNA-WT vs RYZB Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas RYZB's P/E ratio is -57.86. In terms of profitability, DNA-WT's ROE is -0.57%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, DNA-WT is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
DNA-WT vs CBAY Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas CBAY's P/E ratio is -32.81. In terms of profitability, DNA-WT's ROE is -0.57%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, DNA-WT is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check CBAY's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
DNA-WT vs AMLX Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, AMLX has a market cap of 3.7B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while AMLX trades at $29.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas AMLX's P/E ratio is -19.68. In terms of profitability, DNA-WT's ROE is -0.57%, compared to AMLX's ROE of -0.42%. Regarding short-term risk, DNA-WT is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check AMLX's competition here
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD)
DNA-WT vs ACAD Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while ACAD trades at $21.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ACAD's P/E ratio is 9.56. In terms of profitability, DNA-WT's ROE is -0.57%, compared to ACAD's ROE of +0.28%. Regarding short-term risk, DNA-WT is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check ACAD's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
DNA-WT vs IOVA Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, IOVA has a market cap of 3.6B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while IOVA trades at $8.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas IOVA's P/E ratio is -11.01. In terms of profitability, DNA-WT's ROE is -0.57%, compared to IOVA's ROE of -0.30%. Regarding short-term risk, DNA-WT is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check IOVA's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
DNA-WT vs ELVN Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ELVN has a market cap of 3.6B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while ELVN trades at $49.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ELVN's P/E ratio is -29.63. In terms of profitability, DNA-WT's ROE is -0.57%, compared to ELVN's ROE of -0.17%. Regarding short-term risk, DNA-WT is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check ELVN's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
DNA-WT vs TNGX Comparison November 2026
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, TNGX has a market cap of 3.6B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while TNGX trades at $21.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas TNGX's P/E ratio is -25.89. In terms of profitability, DNA-WT's ROE is -0.57%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, DNA-WT is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check TNGX's competition here